clinical trial · NCT07138196
A Study to Evaluate Adrixetinib (Q702) in Adults With Active Chronic Graft-Versus-Host Disease
Qurient Co., Ltd.·phase1·recruiting·n = 18
Chronic Graft-Versus-Host DiseaseAdrixetinib
brief summary
Open-label, dose escalation study to evaluate safety, tolerability pharmacokinetic and pharmacodynamic activity, and efficacy of Adrixetinib (Q702) in subjects with relapsed or refractory active chronic graft-versus-host disease (cGVHD).
started
Dec 23, 2025
primary completion
Oct 23, 2029
completion
Oct 31, 2029
last updated
Dec 30, 2025
official title
A Phase 1b, Open-label Dose Escalation Study to Evaluate the Safety, Pharmacodynamic, Pharmacokinetic and Preliminary Efficacy of Q702 in Subjects With Relapsed or Refractory Active Chronic Graft-versus-Host Disease (cGVHD)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol